Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDR | P35968 | 2/20 | 0.78 |
| ▸ | NPC1 | O15118 | 6/20 | 0.69 |
| ▸ | RAB9A | P51151 | 6/20 | 0.69 |
| ▸ | SMN1; SMN2 | Q16637 | 6/20 | 0.69 |
| ▸ | PKM | P14618 | 3/20 | 0.69 |
| ▸ | MAPT | P10636 | 1/20 | 0.69 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.66 |
| ▸ | MITF | O75030 | 1/20 | 0.66 |
| ▸ | GRM4 | Q14833 | 4/20 | 0.65 |
| ▸ | TP53 | P04637 | 1/20 | 0.62 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.62 |
| ▸ | HTT | P42858 | 2/20 | 0.62 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.62 |
| ▸ | GFER | P55789 | 1/20 | 0.62 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.61 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12197854 | 0.86 | GRM4 (0.83) | KDRNPC1RAB9ASMN1; SMN2PKM | |
| SCHEMBL16592903 | 0.86 | NPC1 (0.69) | KDRNPC1RAB9ASMN1; SMN2PKM | |
| SCHEMBL231897 | 0.85 | KDR (0.78) | KDRNPC1RAB9ASMN1; SMN2PKM | |
| SCHEMBL28871768 | 0.85 | KDR (0.60) | KDRNPC1RAB9ASMN1; SMN2PKM | |
| SCHEMBL28036432 | 0.85 | GAA (0.66) | KDRNPC1RAB9ASMN1; SMN2PKM | |
| SCHEMBL28947571 | 0.84 | NPC1 (0.67) | KDRNPC1RAB9ASMN1; SMN2PKM | |
| SCHEMBL29184186 | 0.84 | KDR (0.76) | KDRNPC1RAB9ASMN1; SMN2PKM | |
| SCHEMBL6037587 | 0.83 | NPC1 (0.65) | KDRNPC1RAB9ASMN1; SMN2PKM | |
| SCHEMBL7988912 | 0.83 | NPC1 (0.65) | KDRNPC1RAB9ASMN1; SMN2PKM | |
| SCHEMBL20990144 | 0.83 | NPC1 (0.67) | KDRNPC1RAB9ASMN1; SMN2PKM |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 38 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-118005608-A | Triazole small molecular organic compound for inhibiting mitochondrial oxidative phosphorylation by specific targeting complex I and application thereof | 华东师范大学 | 2024-05-10 | — | — | CN | claimed |
| US-20030018016-A1 | Cell adhesion inhibitors | BIOGEN IDEC MA, INC. | 2003-01-23 | — | — | US | claimed |
| EP-0805796-B1 | CELL ADHESION INHIBITORS | BIOGEN INC (US) | 2002-12-11 | — | — | EP | claimed |
| US-6376538-B1 | ANTIINFLAMMATORY AGENTS; AUTOIMMUNE DISEASES | BIOGEN, INC. | 2002-04-23 | — | — | US | claimed |
| EP-0805796-A1 | CELL ADHESION INHIBITORS | BIOGEN, INC. (US) | 1997-11-12 | — | — | EP | claimed |
| WO-1996022966-A1 | CELL ADHESION INHIBITORS | BIOGEN, INC. (US) | 1996-08-01 | — | — | WO | claimed |
| CN-119998260-A | Process for preparing amides from esters | 巴斯夫欧洲公司 | 2025-05-13 | — | — | CN | disclosed |
| CN-118439994-A | Preparation method of 2-pyridine carboxamide compound | 江阴迈康升华医药科技有限公司 | 2024-08-06 | — | — | CN | disclosed |
| US-10196392-B2 | Fused heterocyclic compounds as selective BMP inhibitors | VANDERBILT UNIVERSITY (US) | 2019-02-05 | — | — | US | disclosed |
| EP-2900238-B1 | FUSED HETEROCYCLIC COMPOUNDS AS SELECTIVE BMP INHIBITORS | UNIV VANDERBILT (US) | 2017-12-06 | — | — | EP | disclosed |
| US-20170313701-A1 | Fused Heterocyclic Compounds as Selective BMP Inhibitors | VANDERBILT UNIVERSITY | 2017-11-02 | — | — | US | disclosed |
| US-20170313701-A1 | Fused Heterocyclic Compounds as Selective BMP Inhibitors | VANDERBILT UNIVERSITY | 2017-11-02 | — | — | US | disclosed |
| US-9738636-B2 | Fused heterocyclic compounds as selective BMP inhibitors | VANDERBILT UNIVERSITY (US) | 2017-08-22 | — | — | US | disclosed |
| WO-2003007954-A2 | SULFONYL ARYL HYDROXAMATES AND THEIR USE AS MATRIX METALLOPROTEASE INHIBITORS | PHARMACIA CORPORATION (US) | 2003-01-30 | — | — | WO | disclosed |
| US-20030018016-A1 | Cell adhesion inhibitors | BIOGEN IDEC MA, INC. | 2003-01-23 | — | — | US | disclosed |
| EP-0805796-B1 | CELL ADHESION INHIBITORS | BIOGEN INC (US) | 2002-12-11 | — | — | EP | disclosed |
| US-6376538-B1 | ANTIINFLAMMATORY AGENTS; AUTOIMMUNE DISEASES | BIOGEN, INC. | 2002-04-23 | — | — | US | disclosed |
| EP-1142867-A2 | Cell adhesion inhibitors | BIOGEN, INC. (US) | 2001-10-10 | — | — | EP | disclosed |
| EP-0805796-A1 | CELL ADHESION INHIBITORS | BIOGEN, INC. (US) | 1997-11-12 | — | — | EP | disclosed |
| WO-1996022966-A1 | CELL ADHESION INHIBITORS | BIOGEN, INC. (US) | 1996-08-01 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10196392-B2 | Fused heterocyclic compounds as selective BMP inhibitors | BMP1, BMP4, BMP2 | KDR 233/4885NPC1 3037/4885RAB9A 1421/4885 |
| US-20170313701-A1 | Fused Heterocyclic Compounds as Selective BMP Inhibitors | BMP1, BMP4, BMP2 | KDR 233/4885NPC1 3037/4885RAB9A 1421/4885 |
| US-20030018016-A1 | Cell adhesion inhibitors | ICAM1, VCAM1, EPCAM | KDR 2349/4885NPC1 2649/4885RAB9A 1779/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.